How Does a Swedish Nursing Student View Clinical Oncology Care in the United States?

2019 ◽  
Keyword(s):  
United States ◽  
Clinical Oncology ◽  
Nursing Student ◽  
The United States ◽  
Oncology Care ◽  
Student View

American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care

2009 ◽  
Vol 27 (23) ◽  
pp. 3868-3874 ◽  
Author(s):  
Neal J. Meropol ◽  
Deborah Schrag ◽  
Thomas J. Smith ◽  
Therese M. Mulvey ◽  
Robert M. Langdon ◽  
...  
Keyword(s):  
United States ◽  
Health Care ◽  
Clinical Oncology ◽  
Cancer Care ◽  
Cost Effective ◽  
The United States ◽  
Cost Of Care ◽  
High Quality ◽  
American Society ◽  
The Cost

Advances in early detection, prevention, and treatment have resulted in consistently falling cancer death rates in the United States. In parallel with these advances have come significant increases in the cost of cancer care. It is well established that the cost of health care (including cancer care) in the United States is growing more rapidly than the overall economy. In part, this is a result of the prices and rapid uptake of new agents and other technologies, including advances in imaging and therapeutic radiology. Conventional understanding suggests that high prices may reflect the costs and risks associated with the development, production, and marketing of new drugs and technologies, many of which are valued highly by physicians, patients, and payers. The increasing cost of cancer care impacts many stakeholders who play a role in a complex health care system. Our patients are the most vulnerable because they often experience uneven insurance coverage, leading to financial strain or even ruin. Other key groups include pharmaceutical manufacturers that pass along research, development, and marketing costs to the consumer; providers of cancer care who dispense increasingly expensive drugs and technologies; and the insurance industry, which ultimately passes costs to consumers. Increasingly, the economic burden of health care in general, and high-quality cancer care in particular, will be less and less affordable for an increasing number of Americans unless steps are taken to curb current trends. The American Society of Clinical Oncology (ASCO) is committed to improving cancer prevention, diagnosis, and treatment and eliminating disparities in cancer care through support of evidence-based and cost-effective practices. To address this goal, ASCO established a Cost of Care Task Force, which has developed this Guidance Statement on the Cost of Cancer Care. This Guidance Statement provides a concise overview of the economic issues facing stakeholders in the cancer community. It also recommends that the following steps be taken to address immediate needs: recognition that patient-physician discussions regarding the cost of care are an important component of high-quality care; the design of educational and support tools for oncology providers to promote effective communication about costs with patients; and the development of resources to help educate patients about the high cost of cancer care to help guide their decision making regarding treatment options. Looking to the future, this Guidance Statement also recommends that ASCO develop policy positions to address the underlying factors contributing to the increased cost of cancer care. Doing so will require a clear understanding of the factors that drive these costs, as well as potential modifications to the current cancer care system to ensure that all Americans have access to high-quality, cost-effective care.

The Community Clinical Oncology Program (CCOP) story: review of community oncologists' experiences with clinical research trials in cancer with an emphasis on the CCOP of the National Cancer Institute between 1982 and 1987.

1994 ◽  
Vol 12 (8) ◽  
pp. 1718-1723 ◽  
Author(s):  
R W Frelick
Keyword(s):  
United States ◽  
Clinical Research ◽  
Clinical Oncology ◽  
National Cancer Institute ◽  
Positive Impact ◽  
Cancer Control ◽  
The United States ◽  
Background Information ◽  
Cancer Management ◽  
Clinical Research Trials

PURPOSE To review the growth of community physicians' involvement in National Cancer Institute (NCI) clinical research trials as a significant contribution to cancer control, and to show their impact, not yet fully realized, on cancer morbidity and mortality in the United States. DESIGN Background information, based on the personal experience of participants, as well as a review of pertinent literature, portrays the evolution of the clinical research component of community oncology in the United States over the last 25 years. RESULTS Data from Community Clinical Oncology Programs (CCOPs) I and II have been used to outline some of the results of this far-reaching program. CONCLUSION The CCOP was introduced at an appropriate time to expand the clinical trial resources of the NCI, while at the same time helping community oncologists practice state-of-the-art cancer management found in the research protocols. This in turn provided improved resources to manage cancer patients, as most of them are treated in their own communities. CCOPs have also indirectly had a positive impact on the trial processes of the NCI cooperative groups and comprehensive cancer centers, and have helped to widen the scope and hasten progress in cancer-control research and practice.

Clinical Cancer Advances 2010: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

2010 ◽  
Vol 28 (36) ◽  
pp. 5327-5347 ◽  
Author(s):  
Mark G. Kris ◽  
Steven I. Benowitz ◽  
Sylvia Adams ◽  
Lisa Diller ◽  
Patricia Ganz ◽  
...  
Keyword(s):  
United States ◽  
Cancer Research ◽  
Clinical Trials ◽  
Clinical Oncology ◽  
The United States ◽  
Cooperative Group ◽  
Institute Of Medicine ◽  
Group Program ◽  
American Society ◽  
The Right

A MESSAGE FROM ASCO'S PRESIDENT Like many health professionals who care for people with cancer, I entered the field because of specific patients who touched my heart. They still do. In an effort to weave together my personal view of what the American Society of Clinical Oncology (ASCO) stands for and the purpose the organization serves, my presidential theme this year is “Patients. Pathways. Progress.” Patients come first. Caring for patients is the most important, rewarding aspect of being an oncology professional. At its best, the relationship between doctor and patient is compassionate and honest—and a relationship of mutual respect. Many professional organizations have an interest in cancer, but no other society is so focused on the entire spectrum of cancer care, education, and research. Nor is any other society as particularly interested in bringing new treatments to our patients through clinical trials as ASCO is. Clinical trials are the crux for improving treatments for people with cancer and are critical for continued progress against the disease. “Pathways” has several meanings. Some pathways are molecular—like the cancer cell's machinery of destruction, which we have only begun to understand in recent years. But there are other equally important pathways, including the pathways new therapies follow as they move from bench to bedside and the pathways patients follow during the course of their diseases. Improved understanding of these pathways will lead to new approaches in cancer care, allowing doctors to provide targeted therapies that deliver improved, personalized treatment. The best pathway for patients to gain access to new therapies is through clinical trials. Trials conducted by the National Cancer Institute's Cooperative Group Program, a nationwide network of cancer centers and physicians, represent the United States' most important pathway for accelerating progress against cancer. This year, the Institute of Medicine released a report on major challenges facing the Cooperative Group Program. Chief among them is the fact that funding for the program has been nearly flat since 2002. ASCO has called for a doubling of funding for cooperative group research within five years and supports the full implementation of the Institute of Medicine recommendations to revitalize the program. ASCO harnesses the expertise and resources of its 28,000 members to bring all of these pathways together for the greater good of patients. Progress against cancer is being made every day—measurable both in our improved understanding of the disease and in our ability to treat it. A report issued in December 2009 by the National Cancer Institute, the Centers for Disease Control and Prevention, the American Cancer Society, and the North American Association of Central Cancer Registries found that rates of new diagnoses and rates of death resulting from all cancers combined have declined significantly in recent years for men and women overall and for most racial and ethnic populations in the United States. The pace of progress can be and needs to be hastened. Much remains to be done. Sustained national investment in cancer research is needed to bring better, more effective, less toxic treatments to people living with cancer. Pathways to progress continue in the clinic as doctors strive to find the right treatments for the right patients, to understand what represents the right treatments, and to partner with patients and caregivers for access to those treatments. This report demonstrates that significant progress is being made on the front lines of clinical cancer research. But although our nation's investment in this research is paying off, we must never forget the magnitude of what lies ahead. Cancer remains the number two killer of Americans. Future progress depends on continued commitment, from both ASCO and the larger medical community. George W. Sledge Jr, MD President American Society of Clinical Oncology

Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

2013 ◽  
Vol 31 (1) ◽  
pp. 131-161 ◽  
Author(s):  
Bruce J. Roth ◽  
Lada Krilov ◽  
Sylvia Adams ◽  
Carol A. Aghajanian ◽  
Peter Bach ◽  
...  
Keyword(s):  
United States ◽  
Cancer Research ◽  
Clinical Oncology ◽  
Cancer Diagnosis ◽  
Annual Report ◽  
The United States ◽  
Patient Specific ◽  
Molecular Characteristics ◽  
Clinical Cancer ◽  
American Society

A MESSAGE FROM ASCO'S PRESIDENTI am delighted to present you with “Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.” The American Society of Clinical Oncology (ASCO) uses this opportunity each year to share the steady progress occurring in our understanding and treatment of cancer. For 2012, we offer again an inspiring perspective on clinical cancer advances over the past year, but with a cautionary note: if current threats to federal funding materialize, future progress in cancer research will be seriously undermined.Continued progress against cancer. As you read the following pages of this report, I hope you will share my unabashed enthusiasm—and pride—in how far we have come. To appreciate what this progress has meant to the millions of people who receive a cancer diagnosis each year, consider the following: (1) two of three people in the United States live at least 5 years after a cancer diagnosis (up from roughly one of two in the 1970s); (2) the nation's cancer death rate has dropped 18% since the early 1990s, reversing decades of increases; and (3) individuals with cancer are increasingly able to live active, fulfilling lives because of better management of symptoms and treatments with fewer adverse effects.Importance of clinical cancer trials. These dramatic trends—and the advances highlighted in this report—would have been unthinkable without the engine that drives life-saving cancer treatment: clinical cancer research. Advances in technology and in our knowledge of how patient-specific molecular characteristics of the tumor and its environment fuel the growth of cancer have brought new hope to patients. Clinical trials are the key to translating cutting-edge laboratory discoveries into treatments that extend and improve the lives of those with cancer.But progress is only part of the story. Cancer remains a challenge, with many cancers undetected until their latest stages and others resisting most attempts at treatment. Tragically, cancer still kills more than 500,000 people in the United States every year, and its global burden is growing rapidly.Bridges to better care. To conquer cancer, we need to build bridges to the future—bridges that will get scientific advances to the patient's bedside quicker, bridges that will enable us to share information and learn what works in real time, and bridges that will improve care for all patients around the world.At ASCO, we recognize the unique role that oncologists must play. ASCO's “Accelerating Progress Against Cancer: Blueprint for Transforming Clinical and Translational Cancer Research,”1published last year, presents our vision and recommendations to make cancer research and patient care vastly more targeted, more efficient, and more effective. We have also launched a groundbreaking initiative, CancerLinQ, that aims to improve cancer care and speed research by drawing insights from the vast pool of data on patients in real-world settings.Renewing a national commitment to cancer research. We are on the threshold of major advances in cancer prevention, detection, and treatment—but only if, as a nation, we remain committed to this critical endeavor.The federally funded cancer research system is currently under threat by larger federal budget concerns. Clearly, Congress faces a complex budget environment, but now is not the time to retreat from our nation's commitment to conquering a disease that affects nearly all of us. Bold action must be taken to ensure that we can take full advantage of today's scientific and technologic opportunities.Please join me in celebrating our nation's progress against cancer and in recommitting ourselves to supporting cancer research. Millions of lives depend on it.Sandra M. Swain, MDPresidentAmerican Society of Clinical Oncology

A systematic review of evidence for cannabis and cannabinoids as adjuvant therapy in palliative and supportive oncology care.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 12091-12091
Author(s):  
Sebastian Jugl ◽  
Shailina Keshwani ◽  
Lauren Adkins ◽  
Coy D. Heldermon ◽  
Almut Winterstein ◽  
...  
Keyword(s):  
United States ◽  
Systematic Review ◽  
Cancer Patients ◽  
Systematic Reviews ◽  
Meta Analysis ◽  
The United States ◽  
Nausea And Vomiting ◽  
Medical Cannabis ◽  
Qualitative Synthesis ◽  
Oncology Care

12091 Background: Medical cannabis use is increasing significantly in the United States as states reduce restrictions. However, ambiguity concerning the evidence for medical cannabis efficacy and safety, especially in the field of oncology, is persistent. Clinicians therefore face challenges in examining benefits and risks of medical cannabis as adjuvant treatment for cancer patients. This study identifies and evaluates the most recent available evidence for the efficacy of cannabis and cannabinoids as adjuvant in supportive and/or palliative use in patients with cancer. Methods: Electronic databases searched included PubMed, Embase, Web of Science, and Cochrane Library to identify studies published following the latest available systematic review, between July 2016 through October 2019. Studies conducted outside the United States, studies not evaluating cannabis or cannabinoids in Oncology care, and preclinical studies were excluded. Findings were organized in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) framework. Lastly, qualitative synthesis was used to generate summary statements about the role of cannabis and cannabinoids as adjuvant in supportive and/or palliative cancer care. Results: We screened 2,267 articles and included 96 studies in our qualitative synthesis. Among those were 2 RCT’s (1 completed), 6 Systematic reviews with Meta-analysis, 4 Systematic reviews without Meta-analysis, 71 other types of reviews and 13 observational studies. The most frequently reported outcomes assessed were efficacy of cannabis and cannabinoids for: pain (40 of 96; 17 indicating improvement), nausea and vomiting (26 of 96; 20 indicating improvement), cachexia (22 of 96; 2 indicating improvement), and utilization patterns of cannabis and/or cannabinoids among cancer patients (8 of 96). Conclusions: Latest available prevalence estimates indicate that a significant proportion of patients in the United States with cancer use cannabis and/or cannabinoids (18.3-40.0%). There is substantial evidence for the effectiveness of cannabis and cannabinoids in treating cancer-related pain; specifically, oromucosal THC/CBD spray. There is conclusive evidence for the effectiveness of cannabis and cannabinoids in relieving chemotherapy-induced nausea and vomiting; specifically, oral THC. There is inconclusive evidence regarding the effectiveness of cannabis and cannabinoids in treating cancer-related cachexia.

Sign in / Sign up

Export Citation Format

Share Document